Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis (ADAPTsc)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04735432
Recruitment Status : Completed
First Posted : February 3, 2021
Last Update Posted : February 1, 2022
Sponsor:
Information provided by (Responsible Party):
argenx

Brief Summary:
The purpose of this study is to investigate the Pharmacodynamics (PD), Pharmacokinetics (PK), safety, tolerability, immunogenicity, and clinical efficacy of efgartigimod coformulated with recombinant human hyaluronidase PH20 (rHuPH20) as compared to efgartigimod IV infused in patients with generalized myasthenia gravis (gMG). The study duration is approximately 12 weeks. After screening, patients will be randomized to receive either efgartigimod infusions or efgartigimod PH20 subcutaneously (SC)

Condition or disease Intervention/treatment Phase
Generalized Myasthenia Gravis Biological: efgartigimod PH20 SC Biological: efgartigimod IV Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 111 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Open-Label, Parallel-Group Study to Compare the Pharmacodynamics, Pharmacokinetics, Efficacy, Safety, Tolerability, and Immunogenicity of Multiple Subcutaneous Injections of Efgartigimod PH20 SC With Multiple Intravenous Infusions of Efgartigimod in Patients With Generalized Myasthenia Gravis
Actual Study Start Date : February 5, 2021
Actual Primary Completion Date : November 2, 2021
Actual Study Completion Date : December 13, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: efgartigimod PH20 SC
Patients receiving efgartigimod PH20 subcutaneous (SC) treatment
Biological: efgartigimod PH20 SC
Subcutaneous injection with efgartigimod PH20 SC

Experimental: efgartigimod
Patients receiving efgartigimod intravenous (IV) treatment
Biological: efgartigimod IV
Intravenous infusion of efgartigimod




Primary Outcome Measures :
  1. Percent change from baseline in total Immunoglobulin (IgG) levels at day 29 [ Time Frame: at day 29 ]

Secondary Outcome Measures :
  1. Absolute values in total immunoglobulin (IgG) levels over time [ Time Frame: up to 12 weeks ]
  2. Change from baseline in total immunoglobulin (IgG) levels over time [ Time Frame: up to 12 weeks ]
  3. Percent change from baseline in total immunoglobulin (IgG) levels over time [ Time Frame: up to 12 weeks ]
  4. Absolute values in acetylcholine receptor binding autoantibodies (AChR-Ab) levels over time in AChR-Ab positive patients [ Time Frame: up to 12 weeks ]
  5. Change from baseline in acetylcholine receptor binding autoantibodies (AChR-Ab) levels over time in AChR-Ab positive patients [ Time Frame: up to 12 weeks ]
  6. Percent change from baseline in acetylcholine receptor binding autoantibodies (AChR-Ab) levels over time in AChR-Ab positive patients [ Time Frame: up to 12 weeks ]
  7. Absolute values in immunoglobulin IgG subtype levels (IgG1, IgG2, IgG3, and IgG4) over time [ Time Frame: up to 12 weeks ]
  8. Change from baseline in immunoglobulin IgG subtype levels (IgG1, IgG2, IgG3, and IgG4) over time [ Time Frame: up to 12 weeks ]
  9. Percent change from baseline in immunoglobulin IgG subtype levels (IgG1, IgG2, IgG3, and IgG4) over time [ Time Frame: up to 12 weeks ]
  10. Area under the effect curve (AUEC) of the percentage change from baseline total immunoglobulin G [ Time Frame: up to 12 weeks ]
  11. Similar Area under the effect curve (AUEC) for each IgG subtype per dosing interval (days 1-8, days 8-15, days 15-22, and days 22-29), days 1-29, and over the entire study (days 1-71) [ Time Frame: up to 12 weeks ]
  12. Pharmacokinetics (PK) parameters: maximum concentration (Cmax) (after all doses for the IV treatment arm) [ Time Frame: up to 12 weeks ]
  13. Pharmacokinetics (PK) parameters: concentration observed predose (Ctrough) [ Time Frame: up to 12 weeks ]
  14. Incidence of anti-drug antibodies (ADAs) against efgartigimod [ Time Frame: up to 12 weeks ]
  15. Prevalence of anti-drug antibodies (ADAs) against efgartigimod [ Time Frame: up to 12 weeks ]
  16. Incidence of anti-drug antibodies (ADAs) against rHuPH20 in the SC treatment arm [ Time Frame: up to 12 weeks ]
  17. Prevalence of anti-drug antibodies (ADAs) against rHuPH20 in the SC treatment [ Time Frame: up to 12 weeks ]
  18. Incidence of adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: up to 12 weeks ]
  19. Severity of adverse events (AEs) [ Time Frame: up to 12 weeks ]
  20. Number of Myasthenia Gravis Activities of Daily Living (MG-ADL) responders [ Time Frame: up to 12 weeks ]
  21. Percentage of Myasthenia Gravis Activities of Daily Living (MG-ADL) responders [ Time Frame: up to 12 weeks ]
  22. Number of Quantitative Myasthenia Gravis (QMG) responders [ Time Frame: up to 12 weeks ]
  23. Percentage of Quantitative Myasthenia Gravis (QMG) responders [ Time Frame: up to 12 weeks ]
  24. Change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score over time. A higher total score indicates more impairment. [ Time Frame: up to 12 weeks ]
  25. Change from baseline in Quantitative Myasthenia Gravis (QMG) score over time. A higher total score indicates more severe impairment [ Time Frame: up to 12 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Bullet list of each inclusion criterium:

  1. Must be capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  2. At least 18 years of age at the time of signing the informed consent form.
  3. Diagnosed with generalized Myasthenia Gravis (gMG) with confirmed documentation and supported by at least 1 of the following:

    1. History of abnormal neuromuscular transmission demonstrated by single fiber electromyography or repetitive nerve stimulation
    2. History of positive edrophonium chloride test
    3. Demonstrated improvement in Myasthenia Gravis (MG) signs upon treatment with oral acetylcholinesterase (AChE) inhibitors as assessed by the treating physician
  4. Meeting the clinical criteria as defined by the Myasthenia Gravis Foundation of America (MGFA) class II, III, IVa, or IVb

Exclusion Criteria:

Bullet list of each exclusion criterium:

  1. Are pregnant or lactating, or intend to become pregnant during the study or within 90 days after the last dose of Investigational Medicinal Product.
  2. Has any of the following medical conditions:

    1. Clinically significant uncontrolled active or chronic bacterial, viral, or fungal infection at screening
    2. Any other known autoimmune disease that, in the opinion of the investigator, would interfere with an accurate assessment of clinical symptoms of myasthenia gravis or put the participant at undue risk.
    3. History of malignancy unless deemed cured by adequate treatment with no evidence of reoccurrence for ≥3 years before the first administration of the IMP. Participants with the following cancers can be included at any time:

      • adequately treated basal cell or squamous cell skin cancer
      • carcinoma in situ of the cervix
      • carcinoma in situ of the breast
      • incidental histological findings of prostate cancer (TNM Classification of Malignant Tumors stage T1a or T1b).
    4. Clinical evidence of other significant serious diseases, or the participant has had a recent major surgery, or who have any other condition that, in the opinion of the investigator, could confound the results of the study or put the participant at undue risk.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04735432


Locations
Show Show 47 study locations
Sponsors and Collaborators
argenx
Layout table for additonal information
Responsible Party: argenx
ClinicalTrials.gov Identifier: NCT04735432    
Other Study ID Numbers: ARGX-113-2001
First Posted: February 3, 2021    Key Record Dates
Last Update Posted: February 1, 2022
Last Verified: January 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Myasthenia Gravis
Muscle Weakness
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Pathologic Processes
Paraneoplastic Syndromes, Nervous System
Nervous System Neoplasms
Neoplasms by Site
Neoplasms
Paraneoplastic Syndromes
Autoimmune Diseases of the Nervous System
Neurodegenerative Diseases
Neuromuscular Junction Diseases
Neuromuscular Diseases
Autoimmune Diseases
Immune System Diseases